# POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma

> **NCT02466399** · PHASE2 · COMPLETED · sponsor: **Peregrine Ophthalmic** · enrollment: 80 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** POLAT-001
- **DRUG:** Latanoprost ophthalmic solution

## Key facts

- **NCT ID:** NCT02466399
- **Lead sponsor:** Peregrine Ophthalmic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02466399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02466399, "POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02466399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*